
Seven in ten health conversations on ChatGPT happen outside normal clinic hours, according to a report OpenAI gave to Axios in January 2026. [3] A sales representative cannot be in the room at those hours. Neither can a medical information line that closes at 5 p.m. The questions still get asked, and an AI system answers them.
This article compares two sources of commercial intelligence. The first is sales training, which tells a field team what to say. The second is AI answer monitoring, which records what patients, caregivers, and clinicians ask AI systems and what those systems answer. The two sources do different jobs. Most pharmaceutical organizations fund the first one fully and the second one barely. We explain what public evidence supports that gap, what the FDA guidance says about the questions a company did not prompt, and how a team can turn monitoring output into better training, better medical information, and cleaner compliance review.
A note on scope. This article contains no proprietary DrugChatter dataset. Every number comes from a cited public source, or it is a calculation we show in full and label as ours. Where we describe how monitoring works, we describe a method, not a result.
The Short Answer: Training Is Outbound, Monitoring Is Inbound
Sales training is an outbound control. A company decides which approved messages a representative delivers, and trains the representative to deliver them accurately and consistently. AI monitoring is an inbound sensor. It records the questions people ask and the answers they receive, so the company can see where its outbound messages and the customer’s actual questions do not meet.
Four points summarize the argument:
- Customers already ask AI systems about drugs at large scale. In a KFF poll fielded February 24 to March 2, 2026, 32% of US adults said they had used an AI chatbot for health information in the past year. [4]
- Physicians use AI too. The American Medical Association reported on March 12, 2026 that 81% of physicians in its survey use AI professionally. [5]
- Direct access to prescribers has declined. ZS Associates reported that 53% of US physicians placed moderate-to-severe restrictions on pharmaceutical sales representatives in 2015, up from 49% the year before. [6]
- AI answers about drugs are not reliably correct. In a peer-reviewed study of 500 chatbot answers, 126 of 484 evaluated answers had accuracy below 100%. [8]
Together these facts support a simple operating rule: use sales training to control what you say, and use monitoring to find out what you are not being asked, and what others are saying in your place.
What Does the Evidence Show About Customers Asking AI Systems Drug Questions?
The evidence shows large and growing use among patients and physicians. It does not show how many of those questions concern a specific drug, and no public source we reviewed breaks the volume down by brand. We state that limit up front because the figures below describe health questions in general.
How Many US Adults Use AI Chatbots for Health Information?
KFF found that 32% of US adults used an AI chatbot for health information in the past year. The poll surveyed 1,343 adults online and by telephone, in English and Spanish, from February 24 to March 2, 2026. The margin of sampling error is plus or minus 3 percentage points. [4]
“32% of U.S. adults say they used AI chatbots for health information in the past year.” This is a paraphrase of the KFF Tracking Poll on Health Information and Trust, fielded February 24 to March 2, 2026 (n = 1,343). [4]
The KFF data also describes why people ask. Of the users, 65% cited quick or immediate information or support. 41% wanted to look up information before deciding whether to see a provider. 36% felt more comfortable looking up information privately. [4] Each reason maps to a commercial or medical-information question. A person who looks up a drug before an appointment arrives with a prepared set of questions. A person who prefers privacy asks questions they may not ask a clinician.
What Did KFF Find About Follow-Up With a Clinician?
Among adults who asked AI about physical health, 42% did not follow up with a doctor or other health professional. Among those who asked about mental health, 58% did not follow up. [4] For a drug company, this means the AI answer is often the last piece of information the person receives before acting, or before deciding not to act.
How Many Users Share Personal Medical Information With AI?
KFF reported that 41% of AI health users uploaded personal medical information, such as test results or doctors’ notes. That equals 13% of the public. [4] We checked the arithmetic: 32% of adults multiplied by 41% of users gives 13.1%, which matches. Users who upload records ask questions about their own medicines, doses, and results, and they get answers shaped by that data.
How Many People Ask ChatGPT Health Questions Every Day?
OpenAI told Axios that more than 40 million people use ChatGPT daily for health information, and that health care topics make up more than 5% of all ChatGPT messages globally. Users ask 1.6 to 1.9 million health insurance questions per week. In underserved rural communities, users send nearly 600,000 health care messages per week. [3]
Three cautions apply to this source. OpenAI supplied the report to Axios exclusively, so it is a company-reported figure, not an independent audit. The 40 million figure is global, not US-only. And the report counts health use broadly, not drug-specific questions. [3]
What Does the 7-in-10 After-Hours Figure Mean for a Field Team?
Seven in ten health care conversations happen outside normal clinic hours. [3] We calculate this as a ratio of 70 to 30, or about 2.3 after-hours conversations for each conversation during clinic hours. This is our arithmetic on a company-reported share. A field visit happens during clinic hours by definition, so the majority of the AI conversations occur in a window the field team does not cover.
How Many Physicians Use AI, and for What?
The AMA reported that 81% of physicians use AI professionally, based on a survey of nearly 1,700 doctors, published March 12, 2026. [5] The AMA page describes this as more than double the 2023 rate.
The leading use case matters here. Summarizing medical research and standards of care was the most common use, at 39% of physicians, up 33 percentage points from 2023. [5] By our calculation, that implies a 2023 figure of about 6% (39 minus 33). Two in five physicians in this survey use AI to summarize research and standards of care. That is the same activity a sales call used to support.
The AMA page did not state the fieldwork dates, so we cannot place the survey more precisely than its March 2026 publication. [5]
Why Can’t Rep Access Alone Show What Customers Want to Know?
Rep access is a narrow and shrinking channel. It reaches only the prescribers who allow visits, and it records only what a representative chooses to log. The public time series we found ends in 2015, so we label all of the figures in this section as historical.
Timeline: How Prescriber Restrictions on Sales Reps Grew From 2008 to 2015
ZS Associates publishes the AccessMonitor report, which aggregates sales-call records and classifies prescribers as accessible, moderately restricted, or severely restricted. We assembled the public headline figures in the table below. The “restricted” column for 2008 and 2012 is our calculation from the reported “accessible” share, because those sources reported the other side of the split.
| Year | Prescribers with moderate-to-severe restrictions | How derived | Source |
|---|---|---|---|
| 2008 | 23% | Calculated: 100% minus 77% accessible | [9] |
| 2012 | About 35% | Calculated: 26% moderate plus 9% severe | [7] |
| 2014 | 49% | Reported as the prior-year figure; consistent with 51% accessible | [6], [9] |
| 2015 | 53% | Reported | [6] |
From 2012 to 2015, the restricted share rose from about 35% to 53%. That is an increase of 18 percentage points in roughly three years. This is our calculation across report editions with different panels: the 2012 report covered about 350,000 prescribers from more than 200 sales teams, and the 2015 report covered about 400,000 prescribers with data from 70% of US pharmaceutical sales representatives. [7][6] The panels differ, so treat the 18-point change as a direction, not a precise measurement.
Which Specialty Restricts Reps the Most?
Oncology. ZS reported that 61% of oncologists had moderate-to-severe restrictions in 2012. [7] The 2015 PharmExec report said 73% of oncologists were access-restricted, without stating the exact year of that figure. [6] Oncology is also the specialty with the most complex label language and the fastest-changing evidence base.
What We Could Not Find
We did not find a public ZS AccessMonitor headline figure after 2015 that we could verify against a primary page. Readers with an AccessMonitor subscription should replace the 2015 anchor with current data. The direction of the trend is documented. The current level is not in the sources we reviewed.
What a Rep Log Can and Cannot Capture
A call note records an interaction that happened. It does not record a question that was never asked, a question asked after hours, or a question asked of a different source. A representative sees the prescriber who allows a visit. AI monitoring sees questions without regard to whether anyone granted access.
The two views also differ in who asks. A rep log reflects clinicians. KFF data reflects patients. [4] A brand with a strong clinician message and a weak patient answer will not see the gap in field data.
How Is a Sales Training Curriculum Built, and Where Is Its Blind Spot?
A training curriculum starts from the approved message set. Training teams build modules around the label, the clinical trial results the company is permitted to present, and objection-handling guides. The design logic is message-first: the company decides what matters, and trains reps to deliver it.
Message-First Design: What It Does Well
Message-first design controls accuracy and consistency. Every representative delivers the same approved content, which reduces the variance a compliance team must review. This control is the purpose of the system, and AI monitoring does not replace it.
Where Message-First Design Leaves a Gap
The gap is the customer’s question list. A curriculum built from the company’s priorities will cover the company’s priorities. It will not cover a question the company did not think to ask. Two examples of questions that fall outside a message set: a patient who asks whether a drug can be taken with a specific supplement, and a clinician who asks how the drug compares with a competitor in a population the label does not address.
Monitoring does not tell the company what it may say about these questions. It tells the company that the questions exist, how often they appear in a monitored question set, and what AI systems currently answer.
What Is AI Monitoring in Pharma? A Working Definition
AI monitoring is the scheduled collection of answers from AI systems to a defined set of drug-related questions, followed by a comparison of each answer against authoritative sources such as the current prescribing information. In practice a monitoring program has four parts: a question library, a model list, a capture process, and a review process.
What AI Monitoring Measures
A monitoring program can measure whether a drug is mentioned in an answer, whether the answer matches the current label on indication, dosing, and warnings, which sources the answer cites, and how an answer changes between runs. The units are questions and answers. The unit is not a person. A monitoring program does not identify who asked.
What AI Monitoring Does Not Measure
It does not measure real patient behavior directly. It does not establish that a given answer reached a given person. And it does not replace adverse event surveillance. We keep these limits explicit because monitoring data is easy to over-read. A well-run program reports what the AI systems said to the monitored questions, on the dates tested, under the settings used.
How Does DrugChatter’s Chatmon Fit This Definition?
DrugChatter publishes this article, so the disclosure is direct. DrugChatter’s monitoring product, chatmon, maintains a library of questions phrased the way people write them and re-runs those questions across multiple AI models on a recurring schedule. The records it stores include the brand, the question, the model vendor, and the answer. We describe it as a question library tested on a schedule. We do not describe it as a feed of live end-user chat sessions.
For a training team, the practical value is the comparison over time. The same question, run weekly across several models, shows whether an answer changed after a label update, after a competitor event, or after a model update.
How Accurate Are AI Answers About Drugs?
The peer-reviewed evidence we reviewed shows material error rates. It also shows that error rates depend on the model, the date, and the question. A single study does not describe all AI systems today, and this section reports one study with its limits.
What Did the Andrikyan 2025 Study in BMJ Quality & Safety Find?
Andrikyan and colleagues tested Bing Copilot, Microsoft’s search-integrated chatbot, in April 2023. They asked 10 patient questions about each of the 50 most prescribed US outpatient drugs of 2020, which produced 500 answers. The study appeared in BMJ Quality & Safety, volume 34, pages 100 to 109, and was published online on October 1, 2024. [8]
The key results, as reported by the authors: [8]
- Mean accuracy was 88.7%, and 126 of 484 evaluated answers had accuracy below 100%.
- 16 answers (3.3%) scored 0% on accuracy.
- Mean completeness was 76.7%.
- In a 20-answer subset rated by seven experts, 66% were judged potentially harmful. 22% of that subset could cause severe harm or death in extent. The authors state this reflects the extent of possible harm, not its likelihood.
- Mean Flesch Reading Ease was 37.2, which is difficult, roughly college level.
What Does 126 of 484 Mean as a Percentage?
By our calculation, 126 divided by 484 is 26.0%. About one in four evaluated answers contained at least some inaccuracy against the study’s reference standard. We present this as our arithmetic on the authors’ counts. The mean accuracy of 88.7% and the 26.0% share describe different things: the first averages a score, and the second counts answers below a perfect score.
Why This Study Cannot Be Read as a Current Accuracy Rate
The study tested one chatbot in April 2023. AI systems have changed since then. The 20-answer harm subset is small, and the authors’ confidence interval for the 66% figure runs from 50% to 85%. [8] The study shows that fluent AI answers about drugs can be wrong or incomplete. It does not give a current error rate for any product on the market in November 2026. Only repeated testing of the current systems can do that.
Why Does Fluency Not Equal Accuracy in an AI Drug Answer?
Readability and accuracy are separate measures. An answer can read smoothly and still omit a contraindication. The Andrikyan data illustrates the point: completeness averaged 76.7% while the answers were rated difficult to read. [8] A reader who sees a confident paragraph has no signal about which statements the label supports. A monitoring program therefore compares each statement to the label, not to the tone of the answer.
A Taxonomy: Six Types of Customer Question That Training Rarely Covers
The table below is an original classification we propose for this article. It is not an industry standard. It sorts customer questions by the type of intelligence they produce and the function that should own the response.
| Type | Example question form | What monitoring reveals | Primary owner | Training implication |
|---|---|---|---|---|
| 1. Label-gap questions | Can I take this drug with a specific supplement? | Whether AI answers match the interaction section of the label | Medical Information | Teach reps the approved referral path, not an answer |
| 2. Safety and tolerability questions | What are the common side effects, and how long do they last? | Whether warnings are present, omitted, or overstated | Pharmacovigilance and Medical Affairs | Align field language with label wording |
| 3. Access and cost questions | Does insurance cover this drug? What does it cost? | Whether AI cites current support programs or outdated ones | Market Access and Patient Support | Update access modules when AI answers drift |
| 4. Comparative questions | How does this drug compare with a competitor? | Which comparisons AI makes and whether the evidence supports them | Medical Affairs and Competitive Intelligence | Prepare approved comparison materials only where evidence permits |
| 5. Unapproved-use questions | Can this drug be used for a condition outside the label? | Where AI makes off-label statements and how it frames them | Medical Information and Regulatory | Refer through the medical information process; see the regulatory section below |
| 6. Logistics questions | What do I do if I miss a dose? How do I store this drug? | Whether dosing and storage guidance matches the label | Medical Information | Make sure field and patient materials match the label wording |
How to Use the Taxonomy in Practice
Tag each question in the monitoring library with one of the six types. Then report findings by type. A finding such as “type 2 answers omit a boxed warning in three of the models tested” goes to Pharmacovigilance and Regulatory. A finding such as “type 3 answers cite an expired support program” goes to Patient Support and Market Access. The type determines the owner, and the owner determines the action.
Which Type Needs the Most Care?
Type 5, unapproved-use questions, needs the most care because company responses to them are regulated. The next section explains what the guidance says.
What Does FDA Guidance Say About Questions the Company Did Not Prompt?
FDA has published two documents that bear on this topic. The first covers unsolicited requests for off-label information. The second covers firm-initiated communication of scientific information on unapproved uses. Neither document addresses AI chatbots. We read them for the principles they state and flag our interpretation separately.
What the 2011 Draft Guidance on Unsolicited Requests Says
FDA issued “Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices” in December 2011. The copy we reviewed is marked “Draft – Not for Implementation” and “Contains Nonbinding Recommendations.” [1]
The document defines unsolicited requests as requests from persons or entities completely independent of the firm, such as health care professionals, academics, formulary committees, patients, and caregivers. A request prompted in any way by the manufacturer or its representatives is not unsolicited. [1]
FDA lists examples of solicited requests. These include a sales representative who mentions an off-label use and invites a request for more information, and a business reply card or promotional statement that invites such requests. [1]
What Should a Response to an Unsolicited Request Look Like?
The draft says a response should be truthful, balanced, non-misleading, and non-promotional. Medical or scientific personnel, not sales or marketing staff, should generate it. Sales and marketing should have no input on the content. A non-public response goes only to the requester, one-on-one. [1]
What Does the Draft Say About Public Forums?
FDA expressed concern that detailed public responses reach people who did not ask for the information. A firm should respond publicly only when the question is specific to its own named product, and the public response should be limited to the firm’s contact information, with the representative’s affiliation disclosed. The detailed answer should follow privately. [1]
What the January 2025 Final Guidance on Scientific Information on Unapproved Uses Says
FDA finalized “Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products” on January 6, 2025. According to a law-firm summary of the final text, the policy covers firm-initiated communications, not responses to unsolicited questions. [2]
The same summary reports several requirements. The communication should include one or more source publications, such as published reprints or clinical practice guidelines. It should carry the recommended disclosures. It should not be combined with promotional communications about approved uses, although a representative may discuss approved uses and unapproved-use scientific information in the same visit if the two are appropriately separated. [2]
How We Interpret These Documents for AI Monitoring
This section is our interpretation, not legal advice, and a company’s own legal and regulatory staff must decide its policy. Three points follow from the text.
- A question a person types into an AI chatbot is independent of the company. The 2011 draft defines unsolicited requests by independence from the firm. [1] The draft does not mention chatbots, so we do not claim it governs them.
- Monitoring is observation. Recording which questions AI systems receive and answer does not itself prompt a request. A company that seeds off-label content to induce questions would raise the solicitation concern the draft describes. [1]
- Training reps to answer an unapproved-use question in the field is a different decision from learning that the question exists. The 2025 final guidance puts the separation of promotional and unapproved-use content at the center of firm-initiated communication. [2] Compliance should decide any field policy before a training module is written.
How Do You Turn AI Monitoring Output Into Sales Training?
The workflow has six steps. Each step has an owner, and the training team owns only the last one. This division matters because monitoring data enters the company through medical, regulatory, and safety functions before it reaches the field.
Step 1: Build a Question Library From Real Phrasing
Collect questions from sources the company already controls and can use lawfully: medical information inquiry logs, patient support call categories, and the wording patients and clinicians use in public forums. Write each question the way a person writes it. A question library built from internal jargon will test the wrong thing.
Step 2: Choose Models and Fix the Settings
List the AI systems to test, such as ChatGPT, Claude, Gemini, and Perplexity. Record the model version, the date and time, whether web search was enabled, and the geographic context. Without these fields, a later comparison is not reproducible. The sources we reviewed give usage figures for ChatGPT only, so the choice of other platforms rests on where your own audience goes, not on public share data. [3]
Step 3: Capture Answers and Compare Them to the Label
Store each answer verbatim. Compare each factual statement to the current prescribing information. Classify each discrepancy by type and severity. A reviewer with medical training should do the classification for any answer that touches dosing, contraindications, or warnings.
Step 4: Route Findings by Owner
Use the taxonomy above. Send safety-related findings to Pharmacovigilance. Send label discrepancies to Regulatory and Medical Information. Send access findings to Market Access. This routing is where most programs fail, because a monitoring report addressed to “the brand team” rarely produces action from Regulatory or Safety.
Step 5: Decide What Is a Training Issue and What Is Not
Not every finding belongs in sales training. An AI error about a boxed warning needs a regulatory and medical response. A recurring question about a support program may need a new approved field aid. A recurring question about an unapproved use needs a compliance decision. Only approved, reviewed content can become training content.
Step 6: Measure Whether the Change Worked
Re-run the same questions on the same models after the change. Compare the new answers with the old ones. A training change should not be judged by the AI answers alone, because field training does not change what an AI system says. The measurement that links training to monitoring is whether the questions the field team now hears match the questions the monitoring program found, and whether the approved referral path is used.
Comparison Table: Sales Training, Medical Information, and AI Monitoring
The table compares three sources of customer-question intelligence. The comparison is our structure. The factual cells cite sources, and the descriptive cells state practice we observe in the industry, not measured findings.
| Dimension | Field sales and training | Medical Information inquiries | AI answer monitoring |
|---|---|---|---|
| Direction | Outbound: delivers approved messages | Inbound: one-on-one requests to the company | Inbound: records questions and AI answers on a schedule |
| Who is reached | Prescribers who allow visits; 53% of US physicians restricted access in 2015 [6] | People who contact the company directly | Whatever questions the library covers, without regard to access |
| Hours covered | Clinic hours | Company support hours | Any hour; 7 in 10 ChatGPT health conversations occur outside clinic hours [3] |
| Regulatory status of response | Promotional content under company review | Unsolicited-request responses follow FDA’s draft principles [1] | Observation of third-party answers; company response goes through existing review |
| Main limit | Cannot hear unasked questions | Sees only people who call or write | Shows answers to monitored questions, not individual behavior |
What This Means for Each Function
Different teams read the same monitoring output for different reasons. The sections below state the specific use for each.
What This Means for Medical Affairs and Medical Information
Medical Information holds the company’s inquiry log, which records people who contacted the company. Monitoring adds the people who did not. Compare the two lists. A question that appears in AI monitoring and never in the inquiry log is a candidate for a new standard response document. A question that appears in the log and shows a wrong AI answer is a candidate for an urgent label-alignment review.
What This Means for Pharmacovigilance
Monitoring output is not a case source. A wrong answer about a known warning is a communication problem, not a safety signal. If a monitoring run records content that describes an adverse event experienced by an identifiable patient, the company’s own pharmacovigilance procedures govern what happens next. Write those procedures before the program starts, so the monitoring team knows when to escalate.
What This Means for Regulatory Affairs
Regulatory should own the label-comparison rules: which version of the prescribing information is the reference, how discrepancies are classified, and how off-label content is handled. The 2011 draft and the 2025 final guidance supply the principles for the unapproved-use question type. [1][2] Regulatory should also own the rule on whether any company response to AI-generated content is allowed, and through which channel.
What This Means for Brand and Commercial Teams
Brand teams get two new inputs. The first is the list of questions customers ask that the brand message does not address. The second is the share of monitored AI answers that mention the brand and the way they describe it. Neither input changes what the brand may say. Both change where the brand puts its approved content, and which approved content it develops next.
What This Means for Sales Enablement and Field Leadership
Sales enablement receives a question map, reviewed and routed by the functions above. The map is useful in three ways: it tells trainers which questions clinicians are likely to raise, it tells them which referral path to teach, and it gives them a reason to update a module when an AI answer drifts from the label. It does not give trainers new claims to make.
What Should a Rep Do When a Physician Says “ChatGPT Told Me That”?
The rep should stay within approved materials and refer detailed questions to Medical Information. We offer this as a reasonable default grounded in the 2011 draft’s logic, which assigns responses to unsolicited questions to medical or scientific personnel and excludes sales and marketing from content decisions. [1] Each company’s compliance group sets the actual policy. Training should include a short script for this exact moment, because physicians are using AI professionally in large numbers. [5]
Scenario Analysis: Sizing a Monitoring Program With Stated Assumptions
This scenario is a planning exercise, not a finding. All inputs are assumptions we choose and state, and a team should replace them with its own.
Assumptions
- The question library has 200 questions for one brand.
- The program tests 4 AI models.
- Each question runs once per week on each model.
- A medical reviewer examines the 10% of answers that an automated comparison flags as differing from the label.
Calculation
200 questions multiplied by 4 models gives 800 answers per week. Over 52 weeks, that is 41,600 answers. At a 10% review rate, the reviewer sees 80 answers per week, or 4,160 per year. If the flag rate is 25% (we use the 26.0% share from the Andrikyan counts only as a rough reference, since that study tested one chatbot in 2023 [8]), the reviewer sees 200 answers per week.
What the Scenario Shows
The review workload depends more on the flag rate than on the library size. A team that doubles its question library and keeps the same flag rate doubles its review workload. A team that improves its automated comparison reduces the workload without reducing coverage. The practical decision is how many answers a medical reviewer can examine per week, and that number should set the library size.
What the Scenario Does Not Show
It does not predict the real flag rate for any brand. The real rate depends on the models tested, the questions chosen, and the quality of the automated comparison. The first monitoring run is the source of that number.
What Can Go Wrong: Limits of AI Monitoring Data
Monitoring data has four known limits. Teams that state them in every report keep their credibility with Regulatory and Legal.
Sampling Limits
A question library is a sample of possible questions. A monitoring result describes the questions tested, on the dates tested. It does not describe all AI-generated drug information. A report should state the number of questions, the number of models, and the dates.
Model Variability
AI systems can give different answers to the same question on different runs, and models change over time. Record the model version and run date for each answer. Treat a single run as one observation. The comparison over repeated runs carries the information.
Over-Reading Aggregate Statistics
The public figures in this article describe general health use. The Axios report counts health messages overall. [3] The KFF poll counts health information use overall. [4] Neither says how many people asked about a specific drug. A brand team should not convert these figures into a demand estimate for its own product.
Compliance Risk From Acting on the Data
The largest risk is acting on a finding without review. A question about an unapproved use may tempt a team to build field content around it. The guidance documents we reviewed place firm-initiated unapproved-use communication under specific conditions, and separate it from promotion. [2] Route every such finding through Regulatory and Legal before it reaches a training deck.
What Happens Next
We separate what is documented from what we expect. Documented: the use figures cited above, the guidance documents, and the accuracy study. Our expectation, which is a judgment and not a forecast with data behind it: field and medical teams will need a shared question map, because the two groups hear different parts of the same demand.
Three open items would change the analysis. First, a current AccessMonitor figure would update our access timeline, which ends in 2015 in the sources we verified. Second, drug-specific AI query volumes, if any provider publishes them, would let brand teams size demand directly. Third, any FDA statement that addresses AI chatbot content about marketed drugs would change the compliance reading above. We found none in the sources reviewed for this article.
Key Takeaways
- KFF found that 32% of US adults used AI chatbots for health information in the past year (poll fielded February 24 to March 2, 2026; n = 1,343). [4]
- OpenAI reported to Axios that more than 40 million people use ChatGPT daily for health information, and that 7 in 10 health conversations occur outside normal clinic hours. [3]
- The AMA reported that 81% of physicians use AI professionally. [5]
- ZS AccessMonitor reported that 53% of US physicians restricted rep access in 2015. Our calculation puts the 2012-to-2015 rise at about 18 percentage points, with the caveat that the panels differ. [6][7]
- In a study of 500 Bing Copilot answers to questions about the 50 most prescribed US drugs, 126 of 484 evaluated answers had accuracy below 100%, which is 26.0% by our arithmetic. [8]
- FDA’s 2011 draft guidance defines unsolicited requests as those completely independent of the firm, and assigns responses to medical or scientific personnel. [1]
- FDA’s January 2025 final guidance covers firm-initiated communication of unapproved-use scientific information, not unsolicited questions. [2]
- Sales training controls what a company says. AI monitoring shows what people ask and what AI systems answer. The two sources need separate owners and a shared review process.
FAQ
Can a pharmaceutical company use AI chatbot questions to design sales training?
A company can use monitoring findings to learn which questions exist and which referral paths to teach. It cannot create new promotional claims from them. Any resulting field content needs the company’s normal medical, legal, and regulatory review. For unapproved-use questions, the 2025 FDA final guidance on firm-initiated scientific communication applies conditions a company must evaluate first. [2]
Is a question typed into ChatGPT an unsolicited request under FDA guidance?
The 2011 draft defines unsolicited requests as coming from persons or entities completely independent of the firm. [1] A question typed into a chatbot is independent of the firm in that ordinary sense, but the draft does not mention chatbots. We do not read it as settling the point. Ask Regulatory and Legal for the company’s position.
How is AI answer monitoring different from social listening?
Social listening collects what people post publicly. AI answer monitoring collects what AI systems answer to a defined set of questions. The first records human statements. The second records machine-generated statements that people may later read and act on.
Who should own AI monitoring, marketing or medical affairs?
Neither should own it alone. Marketing needs the visibility and perception findings. Medical Affairs, Regulatory, and Pharmacovigilance need the label-accuracy findings. A shared program with defined routing by finding type avoids the failure where a report reaches only the team that cannot act on its most serious items.
Does an inaccurate AI answer about a drug count as an adverse event?
An inaccurate answer is a communication finding, not an adverse event. If monitored content describes an adverse event experienced by an identifiable patient, the company’s pharmacovigilance procedures determine the response. Write the escalation rule before the first monitoring run.
Can AI monitoring replace Medical Information inquiry data?
No. The inquiry log records people who contacted the company. Monitoring records answers to questions in a library. The two sources overlap in subject and differ in who they reach. Compare them, and treat disagreement between them as a finding.
Which AI platforms should a monitoring program test?
Test the platforms your audiences use. The public usage evidence we reviewed covers ChatGPT. [3] KFF measured AI chatbots as a group. [4] For other platforms, use your own audience research, and record the model and version for each run.
How often should the same questions be re-run?
The right interval depends on how fast your brand’s information changes. A weekly run catches label updates and model changes within a week. We offer this as a practical default. No source we reviewed measured the optimal interval.
How many questions does a monitoring library need?
Size the library to the reviewer’s capacity, not to a target count. The scenario above shows that a 200-question library on 4 models produces 800 answers per week, and the review workload then depends on the flag rate. Start with a small library, measure the flag rate, and expand.
Does a fluent AI answer mean the answer is correct?
No. In the Andrikyan study, answers were rated difficult to read and still varied in accuracy and completeness. [8] Check each factual statement against the current prescribing information. Do not use the AI answer as evidence that a medical claim is true.
References
- U.S. Food and Drug Administration. (2011, December). Guidance for industry: Responding to unsolicited requests for off-label information about prescription drugs and medical devices (Draft guidance). U.S. Department of Health and Human Services. https://www.hhs.gov/guidance/sites/default/files/hhs-guidance-documents/FDA/Responding-to-Unsolicited-Requests-for-Off-Label-Information-About-Prescription-Drugs-and-Medical-Devices.pdf
- JD Supra. (2025). FDA finalizes guidance on scientific information on unapproved uses (SIUU) communications (summary of FDA, January 6, 2025, final guidance “Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products”). https://jdsupra.com/legalnews/fda-finalizes-guidance-on-scientific-6055477
- Axios. (2026, January 5). Exclusive: 40 million people turn to ChatGPT for health care (reporting an OpenAI report provided to Axios). https://axios.com/2026/01/05/chatgpt-openai-health-insurance-aca
- KFF. (2026, March 25). KFF tracking poll on health information and trust: Use of AI for health information and advice. https://www.kff.org/health-information-trust/poll-1-in-3-adults-are-turning-to-ai-chatbots-for-health-information-equaling-the-share-who-use-social-media-for-health/
- American Medical Association. (2026, March 12). More than 80% of physicians use AI professionally: AMA survey. https://ama-assn.org/practice-management/digital-health/more-80-physicians-use-ai-professionally-ama-survey
- Pharmaceutical Executive. (2015, September 2). More than half of US physicians place moderate to severe restrictions on pharma sales reps (reporting the ZS Associates AccessMonitor report). https://www.pharmexec.com/view/more-half-us-physicians-place-moderate-severe-restrictions-pharma-sales-reps
- Fierce Pharma. (2012, August 28). Oncologists restrict pharmaceutical sales rep access at accelerating rates (reporting the spring 2012 ZS Associates AccessMonitor report). https://www.fiercepharma.com/pharma/oncologists-restrict-pharmaceutical-sales-rep-access-at-accelerating-rates
- Andrikyan, W., Sametinger, S. M., Kosfeld, F., Jung-Poppe, L., Fromm, M. F., Maas, R., & Nicolaus, H. F. (2025). Artificial intelligence-powered chatbots in search engines: A cross-sectional study on the quality and risks of drug information for patients. BMJ Quality & Safety, 34(2), 100-109. Published online October 1, 2024. https://qualitysafety.bmj.com/content/34/2/100.full.pdf
- PolicyMed. (2014, July). Sales rep access to doctors at all time low: “Accessible prescribers” down from 77% in 2008 to 51% in 2014. https://policymed.com/2014/07/sales-rep-access-to-doctors-at-all-time-low-accessible-prescribers-down-from-77-in-2008-to-51-in-201.html






